683
Because the cellular response to a particular signaling molecule depends on the number of receptor-
Epidermal growth factor (EGF), as its name implies, stimulates the proliferation of many types of epithelial cells (see Chapters 16 and 20), including those that line the ducts of the mammary gland. In about 25 percent of breast cancers, the tumor cells have elevated levels of one particular EGF receptor called HER2. The overproduction of HER2 makes the cells hypersensitive to ambient levels of EGF and related hormones, which are normally too low to stimulate cell proliferation; as a consequence, growth of these tumor cells is inappropriately stimulated by EGF. We will see in Chapter 24 that an understanding of the role of HER2 in certain breast cancers led to the development of monoclonal antibodies that bind HER2 and thereby block signaling by EGF; these antibodies have proved useful in treatment of breast cancer patients whose tumors overexpress HER2.
The HER2–